Insulin sensitivity drugs
Pro Research Analysisby 
Searched over 200M research papers
Insulin Sensitivity Drugs: A Comprehensive Overview
Pioglitazone and Metformin: Effects on Muscle Lipid and Insulin Sensitivity
Pioglitazone, a thiazolidinedione, has been shown to significantly improve insulin sensitivity by reducing intramyocellular lipid (IMCL) levels and redistributing lipid into subcutaneous adipose tissue. In a study involving 23 subjects with impaired glucose tolerance, pioglitazone treatment resulted in a 65% increase in insulin sensitivity and a 34% decrease in IMCL, without changes in muscle lipid oxidative enzymes. This suggests that the improvement in insulin sensitivity was due to lipid redistribution rather than increased lipid oxidation. In contrast, metformin did not show significant changes in insulin sensitivity, IMCL, or adipose tissue volumes in the same study.
HIV Protease Inhibitors and Insulin Sensitivity
Protease inhibitors (PIs) used in HIV treatment have varying effects on insulin sensitivity. A systematic review and meta-analysis of randomized controlled trials found that atazanavir, fosamprenavir, and darunavir did not significantly alter insulin sensitivity. However, lopinavir was associated with reduced glucose disposal rates, indicating decreased insulin sensitivity. The study highlighted the need for routine diabetes mellitus (DM) investigations in patients starting antiretroviral therapy, especially in regions heavily affected by HIV.
ACE Inhibitors vs. ARBs in Hypertensive Patients
Angiotensin-converting enzyme inhibitors (ACEIs) have been found to be more effective than angiotensin receptor blockers (ARBs) in improving insulin sensitivity in hypertensive patients without diabetes. A meta-analysis of clinical studies showed that ACEI treatment resulted in a significant improvement in insulin sensitivity compared to ARB treatment, despite no significant differences in fasting plasma glucose, fasting plasma insulin, or blood pressure control between the two drug classes.
Metformin and Rosiglitazone in PCOS
In nonobese women with polycystic ovary syndrome (PCOS) and normal insulin sensitivity, metformin and rosiglitazone were both effective in increasing ovulatory frequency and reducing serum free testosterone levels. Metformin showed a more significant improvement in insulin sensitivity indices compared to rosiglitazone. The combination of both drugs did not offer additional benefits over metformin alone.
Anakinra: An Anti-Inflammatory Approach
Anakinra, an interleukin-1 receptor antagonist, has shown promise in improving insulin sensitivity in insulin-resistant patients with type 1 diabetes. A study involving 14 patients demonstrated that one week of anakinra treatment led to sustained improvements in insulin sensitivity, glucose profiles, HbA1c levels, and insulin needs over a four-week follow-up period.
Thiazolidinediones: Balancing Benefits and Risks
Thiazolidinediones (TZDs), such as pioglitazone and rosiglitazone, are unique in their primary function of increasing insulin sensitivity. Despite their effectiveness in glycemic control, concerns over side effects have led to a decline in their use. The benefits of TZDs include improved insulin sensitivity and glycemic control, but potential adverse effects necessitate careful consideration and monitoring.
Novel Insulin Sensitizers: (-)-BM 13.0913 and SGLT2 Inhibitors
(-)-BM 13.0913, an alpha-activated carbonic acid, has demonstrated efficacy in improving insulin sensitivity in animal models of type 2 diabetes. This drug enhances glucose uptake and oxidation in adipocytes, suggesting improved insulin responsiveness. Additionally, the SGLT2 inhibitor empagliflozin has been shown to improve insulin sensitivity both as monotherapy and in combination with linagliptin in db/db mice. Empagliflozin treatment resulted in increased glucose disposal rates and decreased hepatic glucose production, contributing to better glycemic control.
Empagliflozin and Brain Insulin Sensitivity
Empagliflozin has also been found to improve insulin sensitivity in the hypothalamus of humans with prediabetes. A clinical trial demonstrated that empagliflozin treatment restored hypothalamic insulin responsiveness, which mediated reductions in fasting glucose and liver fat. This positions SGLT2 inhibitors as a potential pharmacological approach to reverse brain insulin resistance.
Conclusion
Insulin sensitivity drugs encompass a diverse range of mechanisms and effects. From pioglitazone's lipid redistribution to empagliflozin's impact on brain insulin sensitivity, these drugs offer various benefits for managing insulin resistance and associated conditions. However, the choice of drug must consider individual patient profiles and potential side effects to optimize therapeutic outcomes.
Sources and full results
Most relevant research papers on this topic